BACKGROUND: Viridans streptococcal bacteremia (VSB) after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with substantial mortality. Prevention of this serious complication is therefore a high priority. The objective of this study was to evaluate the effect of early vancomycin administration on rates and outcomes of VSB. METHODS: We analyzed the effect of early vancomycin on the incidence of VSB in a cohort of 430 consecutive HSCTs performed during the period of 1 January 1998 to 30 September 2002. The primary end point was time to diagnosis of VSB. Early vancomycin was defined as >or=2 doses of vancomycin between days -7 through +7 after HSCT or diagnosis of VSB, whichever occurred first. Risk factors for VSB were identified in univariate and multivariate Cox proportional hazard models. RESULTS: The incidence of VSB in the cohort was 7.4%. The incidence of VSB in patients who did not receive early vancomycin was 24.8%, compared with 0.3% in patients who did (P<.001). Additional risk factors were female sex, conditioning with total body irradiation, and diagnosis of chronic myelogenous leukemia. CONCLUSIONS: The attributable mortality rate for VSB in our cohort was 21%. Early vancomycin was associated with decreased VSB (hazard ratio, 0.02; 95% confidence interval, 0.003-0.19) after controlling for age, sex, underlying disease, and transplantation variables. The benefits of vancomycin prophylaxis for the prevention of VSB and associated mortality need to be evaluated in a prospective clinical trial.
BACKGROUND: Viridans streptococcal bacteremia (VSB) after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with substantial mortality. Prevention of this serious complication is therefore a high priority. The objective of this study was to evaluate the effect of early vancomycin administration on rates and outcomes of VSB. METHODS: We analyzed the effect of early vancomycin on the incidence of VSB in a cohort of 430 consecutive HSCTs performed during the period of 1 January 1998 to 30 September 2002. The primary end point was time to diagnosis of VSB. Early vancomycin was defined as >or=2 doses of vancomycin between days -7 through +7 after HSCT or diagnosis of VSB, whichever occurred first. Risk factors for VSB were identified in univariate and multivariate Cox proportional hazard models. RESULTS: The incidence of VSB in the cohort was 7.4%. The incidence of VSB in patients who did not receive early vancomycin was 24.8%, compared with 0.3% in patients who did (P<.001). Additional risk factors were female sex, conditioning with total body irradiation, and diagnosis of chronic myelogenous leukemia. CONCLUSIONS: The attributable mortality rate for VSB in our cohort was 21%. Early vancomycin was associated with decreased VSB (hazard ratio, 0.02; 95% confidence interval, 0.003-0.19) after controlling for age, sex, underlying disease, and transplantation variables. The benefits of vancomycin prophylaxis for the prevention of VSB and associated mortality need to be evaluated in a prospective clinical trial.
Authors: J Radocha; P Paterová; A Zavřelová; B Víšek; F Gabalec; H Žemličková; P Žák Journal: Folia Microbiol (Praha) Date: 2017-08-03 Impact factor: 2.099
Authors: Robert R Jenq; Ying Taur; Sean M Devlin; Doris M Ponce; Jenna D Goldberg; Katya F Ahr; Eric R Littmann; Lilan Ling; Asia C Gobourne; Liza C Miller; Melissa D Docampo; Jonathan U Peled; Nicholas Arpaia; Justin R Cross; Tatanisha K Peets; Melissa A Lumish; Yusuke Shono; Jarrod A Dudakov; Hendrik Poeck; Alan M Hanash; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Eric G Pamer; Marcel R M van den Brink Journal: Biol Blood Marrow Transplant Date: 2015-05-11 Impact factor: 5.742
Authors: Mini Kamboj; Dick Chung; Susan K Seo; Eric G Pamer; Kent A Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou Journal: Biol Blood Marrow Transplant Date: 2010-05-26 Impact factor: 5.742
Authors: Mini Kamboj; Nina Cohen; Yao-Ting Huang; Marina Kerpelev; Ann Jakubowski; Kent A Sepkowitz; Genovefa A Papanicolaou; Susan K Seo Journal: Biol Blood Marrow Transplant Date: 2018-11-15 Impact factor: 5.742
Authors: Ann A Jakubowski; Trudy N Small; James W Young; Nancy A Kernan; Hugo Castro-Malaspina; Katherine C Hsu; Miguel-Angel Perales; Nancy Collins; Christine Cisek; Michelle Chiu; Marcel R M van den Brink; Richard J O'Reilly; Esperanza B Papadopoulos Journal: Blood Date: 2007-08-23 Impact factor: 22.113
Authors: Susan K Seo; Kun Xiao; Yao-Ting Huang; Ubonvan Jongwutiwes; Dick Chung; Molly Maloy; Sergio Giralt; Juliet N Barker; Ann A Jakubowski; Genovefa A Papanicolaou Journal: J Infect Date: 2014-06-12 Impact factor: 6.072
Authors: Marcel R M van den Brink; Robert R Jenq; Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Enrico Velardi; Jennifer J Tsai; Ann E Slingerland; Odette M Smith; Lauren F Young; Jyotsna Gupta; Sophia R Lieberman; Hillary V Jay; Katya F Ahr; Kori A Porosnicu Rodriguez; Ke Xu; Marco Calarfiore; Hendrik Poeck; Silvia Caballero; Sean M Devlin; Franck Rapaport; Jarrod A Dudakov; Alan M Hanash; Boglarka Gyurkocza; George F Murphy; Camilla Gomes; Chen Liu; Eli L Moss; Shannon B Falconer; Ami S Bhatt; Ying Taur; Eric G Pamer Journal: Sci Transl Med Date: 2016-05-18 Impact factor: 17.956
Authors: Sun Hee Park; Su Mi Choi; Dong Gun Lee; Jung Hyun Choi; Jin Hong Yoo; Jong Wook Lee; Woo Sung Min; Wan Shik Shin; Chun Choo Kim Journal: J Korean Med Sci Date: 2006-04 Impact factor: 2.153